MediWound to Report First Quarter 2024 Financial Results
MediWound (Nasdaq: MDWD) will release its first quarter 2024 financial results on May 29, 2024. The report will cover the period ending March 31, 2024.
A conference call and live webcast are scheduled for the same day at 8:30 am Eastern Time. The call will discuss financial results, provide corporate updates, and include a Q&A session. Dial-in numbers for various regions and a webcast link are provided. An archived version of the webcast will be available on the MediWound website after the event.
- The scheduled release of the financial results for Q1 2024 signals transparency and provides timely information to investors.
- The conference call and webcast will allow direct communication with management, offering clarity and insights into the company's performance and future plans.
- The availability of an archived webcast ensures that stakeholders who cannot attend the live event can still access the information.
- The press release does not provide any preliminary financial data or performance indicators, which could create uncertainty for investors until the release date.
- The announcement lacks specific details on what will be discussed in the corporate updates, leaving investors without clear expectations.
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time
YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2024 on Wednesday, May 29, 2024.
Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.
Dial-in and call details are as follows:
| Conference Call & Webcast Details | |
| Toll-Free: | 1-833-630-1956 |
| Israel: | 1-80-921-2373 |
| International: | 1-412-317-1837 |
| Webcast: | Click HERE |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline, including the company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant
For more information visit www.mediwound.com and follow the Company on LinkedIn.
| MediWound Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Chief Financial Officer | Managing Director |
| MediWound Ltd. | LifeSci Advisors, LLC |
| ir@mediwound.com | daniel@lifesciadvisors.com |
| Media Contact: | |
| Ellie Hanson | |
| FINN Partners for MediWound | |
| ellie.hanson@finnpartners.com | |
| 929-588-2008 | |
FAQ
When will MediWound release its Q1 2024 financial results?
What time is the MediWound Q1 2024 conference call?
How can I participate in the MediWound Q1 2024 earnings call?
Will the MediWound Q1 2024 webcast be available for replay?
What will be discussed during the MediWound Q1 2024 conference call?
